Brief: Regeneron Collaborates With Trinetx To Access De-Identified Electronic Health Records Of 300 Million Patients To Drive Research And Product Development In Life Sciences And Digital Health Solutions
02/04/2026 22:30
April 2 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: REGENERON COLLABORATES WITH TRINETX TO ACCESS DE-IDENTIFIED ELECTRONIC HEALTH RECORDS OF 300 MILLION PATIENTS TO DRIVE RESEARCH AND PRODUCT DEVELOPMENT IN LIFE SCIENCES AND DIGITAL HEALTH SOLUTIONS Source text: ID:nGNX4DxTSd Further company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)